Compare PNFP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNFP | NUVL |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.1B |
| IPO Year | N/A | 2021 |
| Metric | PNFP | NUVL |
|---|---|---|
| Price | $85.62 | $101.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $112.20 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 1.2M | 435.7K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $163.66 | N/A |
| Revenue Next Year | $7.77 | $1,064.25 |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.57 | $55.54 |
| 52 Week High | $120.39 | $113.02 |
| Indicator | PNFP | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 49.88 |
| Support Level | $83.62 | $98.65 |
| Resistance Level | $90.97 | $107.13 |
| Average True Range (ATR) | 3.37 | 3.97 |
| MACD | -0.91 | -0.15 |
| Stochastic Oscillator | 16.66 | 50.05 |
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.